CDMO/ Specialty intermediates (SI)/Nutritional products (NP) lead revenue growth: 1QFY20 sales were up 5% YoY at INR21.8b (our est. INR22.7b), led by 11% YoY growth in the Pharmaceutical segment. Life Science Ingredients (LSI) sales were down 5% YoY to INR8b, impacting overall growth for the quarter. Particularly, CDMO in Pharma and SI/NP in LSI grew 24%/19%/54% YoY. Generics sales grew at moderate rate of 5% YoY and Chemicals sales declined 26% YoY for the quarter. Benefit of superior product mix offset by increased operating cost: Gross...